Guoqiang Lin - HANSOH PHARMAC Non-Executive Independent Director

All Insiders Germany . 
Stock . HANSOH PHARMAC HD 00001 . Stakeholders . Insider . Guoqiang Lin
3KY Stock  EUR 2.16  0.06  2.70%   

Insider

Guoqiang Lin is Non-Executive Independent Director of HANSOH PHARMAC HD 00001 since 2019.
Age 76
Tenure 5 years
Phone86 21 3177 3517
Webhttp://www.hspharm.com

HANSOH PHARMAC Management Efficiency

The company has return on total asset (ROA) of 0.063 % which means that it generated a profit of $0.063 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1366 %, meaning that it generated $0.1366 on every $100 dollars invested by stockholders. HANSOH PHARMAC's management efficiency ratios could be used to measure how well HANSOH PHARMAC manages its routine affairs as well as how well it operates its assets and liabilities.
HANSOH PHARMAC HD 00001 has accumulated 92.75 M in total debt with debt to equity ratio (D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. HANSOH PHARMAC HD has a current ratio of 6.3, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist HANSOH PHARMAC until it has trouble settling it off, either with new capital or with free cash flow. So, HANSOH PHARMAC's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like HANSOH PHARMAC HD sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for HANSOH to invest in growth at high rates of return. When we think about HANSOH PHARMAC's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Kimitoshi UsuiTsumura Co
N/A
FCS FCISCanSino Biologics
46
Qiang XuCanSino Biologics
50
Kai BeckmannMerck Company
58
Tao ZhuCanSino Biologics
49
Ryouichi MurataTsumura Co
N/A
Shinichiro TakaoHisamitsu Pharmaceutical Co
N/A
Zhu XinCanSino Biologics
50
Masaya OkunoHisamitsu Pharmaceutical Co
N/A
Mitsutoshi TsurutaHisamitsu Pharmaceutical Co
N/A
Jianxiong ZhengGuangzhou Baiyunshan Pharmaceut
53
Xi LuoCanSino Biologics
46
Jun YangGuangzhou Baiyunshan Pharmaceut
53
WingYu LeungCanSino Biologics
49
Jianzhong LiuCanSino Biologics
55
Susumu AdachiTsumura Co
60
Koin TodaTsumura Co
N/A
Shiu WaiCanSino Biologics
55
Peter GuenterMerck Company
61
Christophe WeberTakeda Pharmaceutical
57
John BilbreyElanco Animal Health
63
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals and active pharmaceutical ingredients in the Peoples Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd. HANSOH PHARMAC operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 11645 people. HANSOH PHARMAC HD 00001 (3KY) is traded on Frankfurt Exchange in Germany and employs 10,783 people.

Management Performance

Return On Equity0.14
Return On Asset0.063

HANSOH PHARMAC HD Leadership Team

Elected by the shareholders, the HANSOH PHARMAC's board of directors comprises two types of representatives: HANSOH PHARMAC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HANSOH. The board's role is to monitor HANSOH PHARMAC's management team and ensure that shareholders' interests are well served. HANSOH PHARMAC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HANSOH PHARMAC's outside directors are responsible for providing unbiased perspectives on the board's policies.
Min Hu, Vice President
Shengli Zhong, Vice President Joint Company Secretary
Huijuan Zhong, Chief Executive Officer, Executive Chairlady of the Board
Chuanhe Xu, Senior Vice President
Sheung Chan, Non-Executive Independent Director
Rudi Bao, Senior Vice President
Chunhua Zhong, Senior Vice President
Guoqiang Lin, Non-Executive Independent Director
Dongtao Yang, Non-Executive Independent Director
Yuan Sun, Executive Director
Cuifang Ma, Non-Executive Director
Gongzheng Wu, Senior Vice President
Aifeng Lyu, Executive Director
Yan Li, Joint company secretary

HANSOH Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is HANSOH PHARMAC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.14
Return On Asset0.063
Profit Margin0.27 %
Operating Margin0.28 %
Shares Outstanding5.92 B
Shares Owned By Insiders81.92 %
Shares Owned By Institutions7.99 %
Price To Earning38.60 X
Revenue9.97 B
Gross Profit9.06 B

Currently Active Assets on Macroaxis

CCitigroup
GMGeneral Motors
FFord Motor
GMGeneral Motors
VVisa Class A

Other Information on Investing in HANSOH Stock

HANSOH PHARMAC financial ratios help investors to determine whether HANSOH Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HANSOH with respect to the benefits of owning HANSOH PHARMAC security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY